Oncology Weekly

G6PD inhibition leads to oxidative stress and cell death in tumors, boosting the efficacy of immunotherapies.- https://buff.ly/3yA5eN8

Patients with low G6PD expression have better outcomes with ICIs, suggesting a new therapeutic strategy.- https://buff.ly/3yA5eN8

SRS/FSR for CSM yields high CNN recovery rates and long-term tumor control, with SRS showing quicker improvements. -

SRS/FSR for CSM: Better CNNs Recovery & Radiological Control KEY TAKEAWAYS The study aimed to evaluate CNNs recovery in patients with CSM and assess the effectiveness of treatment. The results revealed that...

ML classifiers' accuracy in predicting PCR in breast cancer evaluated. - https://buff.ly/4bWDWhL

Study shows low G6PD expression in tumors improves immune response and outcomes of immune checkpoint inhibitors. -

G6PD Inhibition Boosts Immunotherapy by Inducing Tumor Cell Death KEY TAKEAWAYS The study aimed to investigate how low G6PD expression affects tumor immunity and ICI treatment outcomes. G6PD inhibition triggers...

Upfront resection in elderly glioblastoma patients significantly improves survival rates.

Upfront Resection Improves Survival in Elderly Glioblastoma KEY TAKEAWAYS The study aimed to determine if resection improves survival over biopsy in elderly patients with glioblastoma through a meta-analysis. ...

Study: SRS/FSR for CSM shows significant CNNs recovery and excellent long-term radiological control. - https://buff.ly/3WMsbWG

Upfront resection improves survival in elderly glioblastoma patients, study reveals.

Upfront Resection Improves Survival in Elderly Glioblastoma KEY TAKEAWAYS The study aimed to determine if resection improves survival over biopsy in elderly patients with glioblastoma through a meta-analysis. ...

Study shows COX-2 overexpression is linked to worse prognosis in breast cancer, correlated with TNM staging and histological grading. -

COX-2 as a Prognostic Marker in BC: A Cross-Sectional Study KEY TAKEAWAYS The study aimed to evaluate COX-2 overexpression as a prognostic marker in BC through comparison with histopathological parameters and TNM...

G6PD inhibition triggers immunogenic cell death, enhancing immunotherapy effectiveness against tumors. -

G6PD Inhibition Boosts Immunotherapy by Inducing Tumor Cell Death KEY TAKEAWAYS The study aimed to investigate how low G6PD expression affects tumor immunity and ICI treatment outcomes. G6PD inhibition triggers...

FDA reviews Immorta Bio's Senovax IND application for NSCLC. Potential breakthrough in lung cancer treatment on the horizon. -

FDA Receives IND Application from Immorta Bio’s SenoVax™ for NSCLC FDA has granted an Investigational New Drug (IND) application to Immorta Bio Inc. to initiate a clinical trial evaluating # the safety, immunogenicity, and...

Study compares ML classifiers for predicting PCR in breast cancer. -

Comparing ML Classifiers for Predicting pCR in BC KEY TAKEAWAYS The study aimed to compare the performance of ML classifiers in predicting pCR in BC using radiomics from pre- and post-contrast T1WI. ...